<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04236323</url>
  </required_header>
  <id_info>
    <org_study_id>Shoulder</org_study_id>
    <nct_id>NCT04236323</nct_id>
  </id_info>
  <brief_title>The Effect of Remifentanil on Rebound Pain</brief_title>
  <official_title>The Effect of Remifentanil on Rebound Pain in Patients Receiving General Anesthesia for Shoulder Arthroplasty After Brachial Plexus Block for Postoperative Pain Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will evaluate the influence of intraoperative remifentanil infusion on the
      postoperative hyperalgesia in patients receiving rotator cuff repair after brachial plexus
      block for postoperative analgesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include 68 patients undergoing rotator cuff repair. All patients will receive
      brachial plexus block for postoperative analgesia, followed by general anesthesia. In the
      experimental group, remifentanil infusion will not be used intraoperatively, and in the
      control group, remifentanil will be infused. After surgery, both groups will be given the
      same postoperative pain management using patient controlled analgesia(PCA), and pain patterns
      will be assessed using the Numerical rating scale (NRS) at 4 hour intervals for 24 hours. The
      primary end point of this study is the total dose of PCA medication over 24 hours.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2020</start_date>
  <completion_date type="Anticipated">January 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 19, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total infused dose of patient controlled analgesia(PCA) drug during 24 hours</measure>
    <time_frame>From end of operation to the 24hours after operation</time_frame>
    <description>Total infused dose of patient controlled analgesia(PCA) drug during first 24 hours after rotor cuff repair under general anesthesia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numerical Ratings Scale</measure>
    <time_frame>Pain levels are checked using Numerical Ratings Scale at 4 hour intervals for 24 hours after surgery</time_frame>
    <description>Degree of pain is assessed using Numerical Ratings Scale at 4 hours for 24 hours after operation. The patients choose one of the digits from 0 to 10, the zero-point is painless, and the ten-point means the one with the most severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total patient's trial to PCA bolus infusion</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>The total number of times patients press the infusion button on the PCA to control pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of postoperative nausea and vomiting</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Postoperative nausea and vomiting is assessed at 24hr after surgery by a face-to face interview</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>not used intraoperative remifentanil infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients aged &lt; 70 years and ASA class &lt; III undergoing rotator cuff repair not used intraoperative remifentanil infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>used intraoperative remifentanil infusion</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Adult patients aged &lt; 70 years and ASA class &lt; III undergoing rotator cuff repair used intraoperative remifentanil infusion maintaining target concentration of 2-6ng/ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Not used remifentanil infusion</intervention_name>
    <description>Remifentanil is not used during operation</description>
    <arm_group_label>not used intraoperative remifentanil infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA class I,II,III

          -  Patients undergoing arthroscopic rotator cuff repair surgery under general anesthesia
             after interscalen brachial plexus block for post operative analgesia

          -  Age ranges from 20 to 70

        Exclusion Criteria:

          -  Patients who didn't agree to study

          -  Patients can't control PCA(Patient-Controlled-Analgesia) independently

          -  Patients who have conciousness disorder or can't express their pain level by
             NRS(Numeric Rating Scale) system

          -  Patients who have severe respiratory disease or hepatic failure

          -  Patinets who have known neuropathy or coagulopathy

          -  Pregnancy

          -  Patients with allegies to the drugs used in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-Tae Kim, MD., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin-Tae Kim, MD., PhD</last_name>
    <phone>02-2072-3664</phone>
    <phone_ext>82</phone_ext>
    <email>jintae73@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jin-Tae Kim</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Tae Kim, MD. PhD</last_name>
      <phone>82-2-2072-3295</phone>
      <email>kimjintae73@dreamwiz.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2020</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jin-Tae Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>hyperalgesia</keyword>
  <keyword>brachial plexus block</keyword>
  <keyword>remifentanil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

